# OnCo record hr-nbl1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/hr-nbl1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "hr-nbl1", "NCT01704716" ;
  schema:name "SIOPEN HR-NBL1"@en ;
  schema:description "Europe's long-running high-risk neuroblastoma trial set busulfan-melphalan as the transplant regimen and showed that adding IL-2 to anti-GD2 therapy added toxicity but not benefit."@en ;
  schema:url <https://onco.cc/trials/hr-nbl1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01704716> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2002-02" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:drugs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/busulfan/> ;
  onco:companies <https://onco.cc/companies/cclg/> ;
  onco:people <https://onco.cc/people/ruth-ladenstein/> .